Novartis awaits pivotal trial results for experimental Lp(a)-lowering heart drug

9 articles · Updated · CNBC · Apr 27

Results from the Phase 3 Horizon trial of pelacarsen, led by Dr. Steve Nissen at Cleveland Clinic, are expected mid-2026 after a year-long delay.
If successful, pelacarsen could address high Lp(a) in one in five people worldwide, potentially creating a new class of heart drugs with projected annual sales of $5.6 billion by 2032.
Competitors Amgen and Lilly are also in late-stage trials, but their results are years away. Increased awareness and screening for Lp(a) may follow if these treatments prove effective, though market uptake could be gradual.

New guidelines urge universal Lp(a) screening. Are we prepared for the results with treatment still unproven?

One in five people has high Lp(a). Are we sure it's only a villain before we try to eliminate it?

Research suggests old cholesterol drugs worked by lowering Lp(a). Have we misunderstood heart disease for a decade?

Could the billion-dollar bet on new cholesterol drugs be cardiology's next major failure?

If new drugs work, who will pay for lifelong treatment for 20% of the global population?